Abdominal pain – a well-known gastrointestinal problem in new pandemic reality. Something to be aware of? Review article
Article Sidebar
Published:
Dec 31, 2020
Keywords:
abdominal pain, COVID-19, IBS, gastrointestinal symptoms, mebeverine
Main Article Content
Abstract
Diagnosing and managing abdominal pain is challenging and demanding of both primary care physicians and specialists. Abdominal pain is often non-specific sign and can mask life-threating conditions. The article discusses the problem – diagnostic and treatment of this symptom in terms of the present pandemic reality.
Article Details
How to Cite
Lipiński , M. (2020). Abdominal pain – a well-known gastrointestinal problem in new pandemic reality. Something to be aware of?. Medycyna Faktow (J EBM), 13(4(49), 453-456. https://doi.org/10.24292/01.MF.0420.1
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Adelman AM, Revicki DA, Magaziner J et al. Abdominal pain in an HMO. Fam Med. 1995; 27(5): 321-5.
2. Adelman AM, Koch H. New visits for abdominal pain in the primary care setting. Fam Med. 1991; 23(2): 122-6.
3. PMR Forum 2022 (access: 18.10.2020).
4. Zhang JJ, Dong X, Cao YY et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy. 2020; 75(7): 1730-41.
5. Poggiali E, Ramos PM, Bastoni D et al. Abdominal Pain: A Real Challenge in Novel COVID-19 Infection. Eur J Case Rep Intern Med. 2020; 7(4): 001632. http://doi.org/10.12890/2020_001632.
6. Naser AY, Dahmash EZ, Al-Rousan R et al. Mental health status of the general population, healthcare professionals, and university students during 2019 coronavirus disease outbreak in Jordan: A cross-sectional study. Brain Behav. 2020; 10(8): e01730.
7. Drossman D. Functional gastrointestinal disorders: history, pathophysiology, clinical features, and Rome IV. Gastroenterology. 2016; 150: 1262-79.
8. Majumdar P, Biswas A, Sahu S. COVID-19 pandemic and lockdown: cause of sleep disruption, depression, somatic pain, and increased screen exposure of office workers and students of India. Chronobiol Int. 2020; 37(8): 1191-200.
9. Pietrzak A, Skrzydło-Radomanska B, Mulak A et al. Guidelines on the management of irritable bowel syndrome. Gastroenterol Rev/Prz Gastroenterol. 2018; 13(4): 259-88. http://doi.org/10.5114/pg.2018.78343.
10. Moujaess E, Kourie HR, Ghosn M. Cancer patients and research during COVID-19 pandemic: A systematic review of current evidence. Crit Rev Oncol Hematol. 2020; 150: 102972.
11. Eccleston C, Cooper TE, Fisher E et al. Non-steroidal anti-inflammatory drugs (NSAIDs) for chronic non-cancer pain in children and adolescents. Cochrane Database Syst Rev. 2017; 8(8): CD012537.
12. Sostres C, Carrera-Lasfuentes P, Lanas A. Non-steroidal anti-inflammatory drug related upper gastrointestinal bleeding: types of drug use and patient profiles in real clinical practice. Curr Med Res Opin. 2017; 33(10): 1815-20.
13. Lipinski M. Proton pump inhibitors – principles of therapy including patients with gastroesophageal reflux disease. Lekarz POZ. 2019; 5(3): 275-80.
14. Wang X, Lei SM, Le S et al. Bidirectional Influence of the COVID-19 Pandemic Lockdowns on Health Behaviors and Quality of Life among Chinese Adults. Int J Environ Res Public Health. 2020; 17(15): 5575.
15. Hou X, Chen S, Zhang Y et al. Quality of life in patients with Irritable Bowel Syndrome (IBS), assessed using the IBS-Quality of Life (IBS-QOL) measure after 4 and 8 weeks of treatment with mebeverine hydrochloride or pinaverium bromide: results of an international prospective observational cohort study in Poland, Egypt, Mexico and China. Clin Drug Investig. 2014; 34(11): 783-93.
16. Darvish-Damavandi M, Nikfar S, Abdollahi M. A systematic review of efficacy and tolerability of mebeverine in irritable bowel syndrome. World J Gastroenterol. 2010; 16(5): 547-53. http://doi.org/10.3748/wjg.v16.i5.547.
17. Maev IV, Kucheravy YA, Tsukanov VV et al. Effectiveness of mebeverine in patients with post-cholecystectomy gastrointestinal spasm: results of prospective observational program “odyssey”. Ter Arkh. 2018; 90(8): 40-7.
2. Adelman AM, Koch H. New visits for abdominal pain in the primary care setting. Fam Med. 1991; 23(2): 122-6.
3. PMR Forum 2022 (access: 18.10.2020).
4. Zhang JJ, Dong X, Cao YY et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy. 2020; 75(7): 1730-41.
5. Poggiali E, Ramos PM, Bastoni D et al. Abdominal Pain: A Real Challenge in Novel COVID-19 Infection. Eur J Case Rep Intern Med. 2020; 7(4): 001632. http://doi.org/10.12890/2020_001632.
6. Naser AY, Dahmash EZ, Al-Rousan R et al. Mental health status of the general population, healthcare professionals, and university students during 2019 coronavirus disease outbreak in Jordan: A cross-sectional study. Brain Behav. 2020; 10(8): e01730.
7. Drossman D. Functional gastrointestinal disorders: history, pathophysiology, clinical features, and Rome IV. Gastroenterology. 2016; 150: 1262-79.
8. Majumdar P, Biswas A, Sahu S. COVID-19 pandemic and lockdown: cause of sleep disruption, depression, somatic pain, and increased screen exposure of office workers and students of India. Chronobiol Int. 2020; 37(8): 1191-200.
9. Pietrzak A, Skrzydło-Radomanska B, Mulak A et al. Guidelines on the management of irritable bowel syndrome. Gastroenterol Rev/Prz Gastroenterol. 2018; 13(4): 259-88. http://doi.org/10.5114/pg.2018.78343.
10. Moujaess E, Kourie HR, Ghosn M. Cancer patients and research during COVID-19 pandemic: A systematic review of current evidence. Crit Rev Oncol Hematol. 2020; 150: 102972.
11. Eccleston C, Cooper TE, Fisher E et al. Non-steroidal anti-inflammatory drugs (NSAIDs) for chronic non-cancer pain in children and adolescents. Cochrane Database Syst Rev. 2017; 8(8): CD012537.
12. Sostres C, Carrera-Lasfuentes P, Lanas A. Non-steroidal anti-inflammatory drug related upper gastrointestinal bleeding: types of drug use and patient profiles in real clinical practice. Curr Med Res Opin. 2017; 33(10): 1815-20.
13. Lipinski M. Proton pump inhibitors – principles of therapy including patients with gastroesophageal reflux disease. Lekarz POZ. 2019; 5(3): 275-80.
14. Wang X, Lei SM, Le S et al. Bidirectional Influence of the COVID-19 Pandemic Lockdowns on Health Behaviors and Quality of Life among Chinese Adults. Int J Environ Res Public Health. 2020; 17(15): 5575.
15. Hou X, Chen S, Zhang Y et al. Quality of life in patients with Irritable Bowel Syndrome (IBS), assessed using the IBS-Quality of Life (IBS-QOL) measure after 4 and 8 weeks of treatment with mebeverine hydrochloride or pinaverium bromide: results of an international prospective observational cohort study in Poland, Egypt, Mexico and China. Clin Drug Investig. 2014; 34(11): 783-93.
16. Darvish-Damavandi M, Nikfar S, Abdollahi M. A systematic review of efficacy and tolerability of mebeverine in irritable bowel syndrome. World J Gastroenterol. 2010; 16(5): 547-53. http://doi.org/10.3748/wjg.v16.i5.547.
17. Maev IV, Kucheravy YA, Tsukanov VV et al. Effectiveness of mebeverine in patients with post-cholecystectomy gastrointestinal spasm: results of prospective observational program “odyssey”. Ter Arkh. 2018; 90(8): 40-7.